Meeting
2024 ASCO Annual Meeting
Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program.
Authors
Emmanouil S. Saloustros
On behalf of the Hellenic Society of Medical Oncology, Athens, Greece
Emmanouil S. Saloustros , Michael Liontos , Eleni Timotheadou , Charalampos Andreadis , Efthymia Skafida , John Syrios , Antonia Kalykaki , Konstantinos Koutsoukos , Georgios Kesisis , Ioannis Boukovinas , Anastasios L. Boutis , Pavlos Papakotoulas , Dimitrios C. Ziogas , Sofia Karageorgopoulou , Stylianos Giassas , Evangelos Lianos , Natalia Chatzifoti , Fotini Papageorgiou , Zacharenia (Zenia) Saridaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3146)
DOI
10.1200/JCO.2024.42.16_suppl.3146
Abstract #
3146
Poster Bd #
291
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski
Poster
2022 ASCO Annual Meeting
Establishment of a novel BRCAness score that predicts response to PARP inhibitors.
First Author: Masanori Oshi
Poster
2015 ASCO Annual Meeting
Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.
First Author: Roshni Deepa Kalachand